LMLuciana de Freitas Velloso Monte

Luciana de Freitas Velloso Monte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luciana de Freitas Velloso Monte has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CFTR Modulators in Brazil: Not for Everyone—A Comparison of Ineligibility Across Different Regions

    by Edna Lúcia D' Souza, Victor Hugo Valença Bomfim, Luciana de Freitas Velloso Monte, Laís Ribeiro Mota, Gabriel Souza Medrado Nunes, Regina Terse‐Ramos, Elenara da Fonseca Andrade Procianoy, Luiz Vicente Ribeiro Ferreira da Silva‐Filho

    Objectives: To evaluate the prevalence of ineligibility for Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) and to compare data from four centers in Brazil, considering the racial/ethnic background of each population. Methods: This cross‐sectional study used data from the Brazilian Cystic Fibrosis (CF) Registry. Individuals with a confirmed diagnosis of CF by the identification of two variants in the CFTR gene and/or elevated sweat chloride levels were included. Variables studied were treatment center, age at diagnosis, current age, sex, race/ethnicity, genotype, and ineligibility for ETI and IVA. The chi‐square test compared the distribution of race/ethnicity across centers and associations between ineligibility, treatment center, and the presence of the 3120 + 1 G > A variant. Binary logistic regression was applied to assess the strength of association between the main variables. Results: Six hundred forty‐nine individuals were included, with a median age at diagnosis and current age of 0.25 and 11.6 years, respectively. One hundred thirty‐eight participants (21.26%) were ineligible for ETI or IVA. Racial/ethnic distribution varied across centers, in the total sample, and among ineligible individuals. Non‐White individuals were 20% more likely to be ineligible than White individuals. The ineligibility for ETI did not vary significantly among the centers. Conclusions: The ineligibility for ETI was high across all analyzed regions, but was not different among the centers. In Brazil, characterized by widespread admixture, the public health policies must consider the genotypic heterogeneity and wide variation in ancestry of the Brazilian population.

  • Open Access

    Best clinical practice for imaging in cystic fibrosis referral centers in Brazil: a Delphi consensus panel approach

    by 2 Leonardo A Pinto1, Antonio Fernando Ribeiro3, Edna Lúcia D’ Souza4, Luciana F V Monte5, 7 Vinicius Gomes6, Sergio San Juan Dertkigil8, Isabela Silva Müller9

  • Open Access

    Baseline characteristics of patients from the Brazilian Severe Asthma Registry: the REBRAG study

    by Paulo Marcio Pitrez1, Débora Carla Chong-Silva2, Faradiba Sarquis Serpa3, Adelmir Souza-Machado4, Adalberto Sperb Rubin1, Amanda da Rocha Oliveira Cardoso5, Adyléia Aparecida Dalbo Contrera Toro6, Laura Maria de Lima Belizario Facury Lasmar7, Daniela Cavalet Blanco8, Luciana de Freitas Velloso Monte9, et al.

    Objective: To describe the impact of severe asthma in a real-life cohort in Brazil, reporting on baseline clinical characteristics, access to treatment, and clinical remission under treatment with biologics. Methods: Severe asthma patients > 6 years of age were recruited from 23 centers in Brazil. Data on clinical characteristics, lung function, biomarkers, prescribed therapies, and clinical remission under treatment were collected at the baseline visit. Results: A total of 417 patients were recruited. Of the 162 adult patients, 71% had a history of hospitalization, with 31% having experienced more than two severe exacerbations in the last 12 months and 6% having experienced cardiopulmonary arrest. Allergic and eosinophilic phenotypes were the most common phenotypes in all age groups, with the T2-low phenotype being observed in 10% of the pediatric patients and in 20% of the adult patients. Only 10% of the adult patients and 1% of the pediatric patients were receiving maintenance oral corticosteroids, whereas 41% of the adult patients were under treatment with biologics, with clinical remission being achieved in 20%. Conclusions: Severe asthma in Brazil still results in a high disease burden, with less than half of the patients receiving treatment with biologics and clinical remission being achieved in a subgroup of patients treated with biologics for more than 12 months. Achieving disease control remains a major clinical and health care challenge, requiring further actions from specialists and health care providers, as well as additional studies.


  • Open Access

    Oral health in individuals with cystic fibrosis: A cross-sectional study

    by Daniela Abreu de Moraes, Érica Negrini Lia, Letícia Maria Tenório Jácome, Carolina de Azevedo Pedrosa Cunha, Luciana de Freitas Velloso Monte


  • Open Access

    Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)

    by Rodrigo Abensur Athanazio1, Suzana Erico Tanni8, Juliana Ferreira1, 4 Paulo de Tarso Roth Dalcin3, Marcelo B de Fuccio5, Concetta Esposito6, Mariane Gonçalves Martynychen Canan7, Liana Sousa Coelho8, Mônica de Cássia Firmida9, Marina Buarque de Almeida2, et al.

    Cystic fibrosis (CF) is a genetic disease that results in dysfunction of the CF transmembrane conductance regulator (CFTR) protein, which is a chloride and bicarbonate channel expressed in the apical portion of epithelial cells of various organs. Dysfunction of that protein results in diverse clinical manifestations, primarily involving the respiratory and gastrointestinal systems, impairing quality of life and reducing life expectancy. Although CF is still an incurable pathology, the therapeutic and prognostic perspectives are now totally different and much more favorable. The purpose of these guidelines is to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of the pulmonary symptoms of CF in Brazil. Questions in the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) format were employed to address aspects related to the use of modulators of this protein (ivacaftor, lumacaftor+ivacaftor, and tezacaftor+ivacaftor), use of dornase alfa, eradication therapy and chronic suppression of Pseudomonas aeruginosa, and eradication of methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex. To formulate the PICO questions, a group of Brazilian specialists was assembled and a systematic review was carried out on the themes, with meta-analysis when applicable. The results obtained were analyzed in terms of the strength of the evidence compiled, the recommendations being devised by employing the GRADE approach. We believe that these guidelines represent a major advance to be incorporated into the approach to patients with CF, mainly aiming to favor the management of the disease, and could become an auxiliary tool in the definition of public policies related to CF.


  • Open Access

    Microbiological contamination of nebulizers used by cystic fibrosis patients: an underestimated problem

    by Barbara Riquena, Luciana de Freitas Velloso Monte, Agnaldo José Lopes, Luiz Vicente Ribeiro Ferreira da Silva-Filho, Neiva Damaceno, Evanirso da Silva Aquino, Paulo Jose Cauduro Marostica, José Dirceu Ribeiro

    Objective: Home nebulizers are routinely used in the treatment of patients with cystic fibrosis (CF). This study aims to evaluate the contamination of nebulizers used for CF patients, that are chronically colonized by Pseudomonas aeruginosa, and the association of nebulizer contamination with cleaning, decontamination and drying practices. Methods: A cross-sectional, observational, multicenter study was conducted in seven CF reference centers in Brazil to obtain data from medical records, structured interviews with patients/caregivers were performed, and nebulizer’s parts (interface and cup) were collected for microbiological culture. Results: overall, 77 CF patients were included. The frequency of nebulizer contamination was 71.6%. Candida spp. (52.9%), Stenotrophomonas maltophilia (11.9%), non-mucoid P. aeruginosa (4.8%), Staphylococcus aureus (4.8%) and Burkholderia cepacia complex (2.4%) were the most common isolated pathogens. The frequency of nebulizers’ hygiene was 97.4%, and 70.3% of patients reported cleaning, disinfection and drying the nebulizers. The use of tap water in cleaning method and outdoor drying of the parts significantly increased (9.10 times) the chance of nebulizers’ contamination. Conclusion: Despite the high frequency hygiene of the nebulizers reported, the cleaning and disinfection methods used were often inadequate. A significant proportion of nebulizers was contaminated with potentially pathogenic microorganisms for CF patients. These findings support the need to include patients/caregivers in educational programs and / or new strategies for delivering inhaled antibiotics.